Sci Pharmtech (TPE:4119) Scaled Net Operating Assets: 0.92 (As of Dec. 2025)


TPE:4119 Sci Pharmtech Inc TPE:4119
67 GF Score
Price NT$45.10
GF Value NT$96.61
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Sci Pharmtech Scaled Net Operating Assets?

Sci Pharmtech TPE:4119 67 Scaled Net Operating Assets is 0.92 as of Dec. 2025. GuruFocus rates TPE:4119 with a GF Score™ of 67/100 and a GF Value™ of NT$96.61 (Possible Value Trap). The stock has 8 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sci Pharmtech's operating assets for the quarter that ended in Dec. 2025 was NT$6,812 Mil. Sci Pharmtech's operating liabilities for the quarter that ended in Dec. 2025 was NT$505 Mil. Sci Pharmtech's Total Assets for the quarter that ended in Sep. 2025 was NT$6,853 Mil. Therefore, Sci Pharmtech's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.92.


Sci Pharmtech Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Sci Pharmtech's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sci Pharmtech Scaled Net Operating Assets Chart

Sci Pharmtech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.93 1.03 0.86 0.88

Sci Pharmtech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.83 0.84 0.89 0.92

TPE:4119 vs ZTS, UTHR: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sci Pharmtech Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sci Pharmtech's Scaled Net Operating Assets falls into.


TPE:4119
67GF Score
Sci Pharmtech Inc TPE:4119
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sci Pharmtech Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sci Pharmtech's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(6812.05-505.182)/7200.781
=0.88

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6886.846 - 74.796
=6812.05

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1492.364 - 302.851 - 684.331
=505.182

Sci Pharmtech's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Sep. 2025 )
=(6812.05-505.182)/6853.184
=0.92

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6886.846 - 74.796
=6812.05

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1492.364 - 302.851 - 684.331
=505.182

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.92 mean?
Sci Pharmtech (TPE:4119) has a Scaled Net Operating Assets of 0.92 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sci Pharmtech and its competitors.
Is Sci Pharmtech's Scaled Net Operating Assets too high?
Sci Pharmtech's current Scaled Net Operating Assets is 0.92. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Scaled Net Operating Assets compare to ZTS and UTHR?
Sci Pharmtech's Scaled Net Operating Assets of 0.92 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sci Pharmtech and its competitors. Sci Pharmtech's current Scaled Net Operating Assets is 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$96.61, compared to a current price of NT$45.10 — trading 53.3% below its estimated fair value. The current Scaled Net Operating Assets is 0.92. Sci Pharmtech's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Scaled Net Operating Assets is 0.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sci Pharmtech (TPE:4119) Overvalued in 2026?

Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued. The current stock price of NT$45.10 is trading 53.3% below its estimated GF Value™ of NT$96.61. GuruFocus considers Sci Pharmtech to be Possible Value Trap.

Key valuation signals for TPE:4119:

  • Scaled Net Operating Assets: 0.92
  • GF Value™: NT$96.61 vs. price of NT$45.10 (53.3% below fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sci Pharmtech Business Description

Address No.61, Lane 309, Haihu North Road, Luzhu District, Taoyuan, TWN, 33856
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score

Get the complete analysis for TPE:4119

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$45.10
Price
NT$96.61
GF Value